Catalent, Inc. (CTLT)

NYSE: CTLT · IEX Real-Time Price · USD
98.62
-2.14 (-2.12%)
May 18, 2022 12:27 PM EDT - Market open
Market Cap17.67B
Revenue (ttm)4.70B
Net Income (ttm)486.90M
Shares Out179.21M
EPS (ttm)3.22
PE Ratio30.59
Forward PE22.68
Dividendn/a
Ex-Dividend Daten/a
Volume323,650
Open99.41
Previous Close100.76
Day's Range98.42 - 100.57
52-Week Range86.34 - 142.64
Beta1.38
AnalystsBuy
Price Target140.92 (+42.9%)
Earnings DateMay 3, 2022

About CTLT

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary ...

IndustryPharmaceuticals
IPO DateJul 31, 2014
Employees17,300
Stock ExchangeNYSE
Ticker SymbolCTLT
Full Company Profile

Financial Performance

In 2021, Catalent's revenue was $4.00 billion, an increase of 29.22% compared to the previous year's $3.09 billion. Earnings were $585.00 million, an increase of 164.71%.

Financial Statements

Analyst Forecast

According to 22 analysts, the average rating for CTLT stock is "Buy." The 12-month stock price forecast is 140.92, which is an increase of 42.89% from the latest price.

Price Target
$140.92
(42.89% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Catalent Shares Jump As Investors Cheer Revised, Better Than Expected FY22 Outlook

Catalent Inc (NYSE: CTLT) reported Q3 FY22 sales of $1.27 billion, +21% Y/Y as reported, or 23% in constant currency, edging out analysts' average expectation of $1.22 billion. Adjusted EPS of $1.04, co...

2 weeks ago - Benzinga

Catalent (CTLT) Q3 Earnings Beat Estimates, FY22 View Up

Catalent's (CTLT) robust performance across most of its segments drives its third-quarter fiscal 2022 top line.

2 weeks ago - Zacks Investment Research

Catalent (CTLT) Tops Q3 Earnings and Revenue Estimates

Catalent (CTLT) delivered earnings and revenue surprises of 10.64% and 4.38%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Catalent, Inc. Reports Third Quarter Fiscal 2022 Results

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient tr...

2 weeks ago - Business Wire

Should You Buy Catalent (CTLT) Ahead of Earnings?

Catalent (CTLT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 weeks ago - Zacks Investment Research

Catalent (CTLT) Reports Next Week: Wall Street Expects Earnings Growth

Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago - Zacks Investment Research

Why Catalent (CTLT) is Poised to Beat Earnings Estimates Again

Catalent (CTLT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

3 weeks ago - Zacks Investment Research

Catalent's (CTLT) Latest Manufacturing Suites to Boost Capacity

Catalent's (CTLT) latest site expansion is expected to significantly boost its business.

1 month ago - Zacks Investment Research

Catalent, Inc. Announces Third Quarter Fiscal Year 2022 Earnings Conference Webcast

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene the...

1 month ago - Business Wire

Catalent's (CTLT) Latest Buyout to Expand Its Global Footprint

Catalent's (CTLT) latest acquisition is likely to significantly enhance its global Biologics business.

1 month ago - Zacks Investment Research

Stocks Like Catalent and PerkinElmer Are Benefiting From Biotech's 'Gold Rush' — Here's Why

Beyond the catchy biotech names splashed across the headlines, experts say medical stocks in the background, like Catalent and PerkinElmer, are maybe more likely to strike it rich. Investor's Business D...

Other symbols:PKI
1 month ago - Investors Business Daily

Here's Why Catalent (CTLT) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

1 month ago - Zacks Investment Research

Catalent's (CTLT) New Project Completion Expands Global Footprint

Catalent's (CTLT) latest facility transformation is likely to significantly enhance the global Biologics business.

1 month ago - Zacks Investment Research

Catalent, Inc. to Present at the KeyBanc Life Sciences & MedTech Investor Forum

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments acro...

2 months ago - Business Wire

Is There A Better Pick Over West Pharmaceutical Services Stock?

We believe that Catalent stock, a global solutions provider for drugs, biologics, gene therapies, and consumer healthcare products, currently is an attractive pick over West Pharmaceutical Services, bes...

2 months ago - Forbes

Catalent Publishes Third Annual Corporate Responsibility Report

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better pati...

2 months ago - Business Wire

Reasons to Retain Catalent (CTLT) Stock in Your Portfolio

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.

2 months ago - Zacks Investment Research

Catalent's (CTLT) New Tie-Up to Provide Better Patient Access

Catalent's (CTLT) latest collaboration is expected to enable it to provide customers access to the TFF technology.

2 months ago - Zacks Investment Research

Catalent (CTLT) Down 3.4% Since Last Earnings Report: Can It Rebound?

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

Edenbridge Pharmaceuticals Announces the Launch of DARTISLA ODT

PARSIPPANY, N.J.--(BUSINESS WIRE)--Edenbridge Pharmaceuticals, LLC (“Edenbridge”) today announced that DARTISLA ODT (glycopyrrolate) is now available by prescription in the United States through Phil, t...

2 months ago - Business Wire

Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows

It takes guts to catch a falling knife, but sometimes the reward is worth the risk.

Other symbols:PINSSHOP
2 months ago - The Motley Fool

Catalent (CTLT) Q2 Earnings Top Estimates, FY22 View Up

Catalent's (CTLT) robust performance across most of its segments drives its second-quarter fiscal 2022 top line.

3 months ago - Zacks Investment Research

Catalent (CTLT) Surpasses Q2 Earnings and Revenue Estimates

Catalent (CTLT) delivered earnings and revenue surprises of 7.14% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Catalent's Q2 Earnings Beat Street View, Lifts FY22 Guidance

Catalent Inc CTLT has reported Q2 FY22 sales of $1.22 billion, +34% Y/Y as reported, or 35% in constant currency, edging out analysts' average expectation of $1.15 billion. [LIVE NOW ON YOUTUBE] Click H...

3 months ago - Benzinga

Catalent, Inc. Reports Second Quarter Fiscal 2022 Results

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient tr...

3 months ago - Business Wire